ZNF471

ZNF471 is a KRAB-domain zinc finger transcription factor that functions as a tumor suppressor across multiple epithelial cancers by acting as a sequence-specific regulator of growth- and motility-associated promoters (PMID:29610526, PMID:33203470). As a transcriptional repressor it binds target promoters such as TFAP2A and PLS3 and recruits the co-repressor KAP1 to nucleate H3K9me3-marked heterochromatin and silence transcription (PMID:29610526); it also directly represses c-Myc by binding its promoter (PMID:38749608). In a context-dependent manner ZNF471 can instead activate transcription, binding the MAPK10/JNK3 promoter to induce JNK3 and PCDH family expression in esophageal squamous carcinoma (PMID:32089740). Downstream of these transcriptional activities, ZNF471 suppresses AKT, PI3K/AKT/mTOR, and Wnt/β-catenin signaling, thereby inhibiting proliferation, invasion, epithelial-mesenchymal transition, and tumor cell stemness (PMID:33203470, PMID:38169650, PMID:40326975). Its activity is gated by post-translational and physical regulation: N-glycosylation at Asn358 destabilizes the protein and limits its nuclear translocation, so loss of glycosylation enhances stability and nuclear repressor function (PMID:38749608), and it forms complexes with BANP and MIS18A that contribute to pathway suppression (PMID:38169650, PMID:42155792). Expression of ZNF471 is itself controlled in trans, being derepressed by the LIFR-AS1/miR-942-5p axis in lung cancer (PMID:32489316).

1. 2018 High

   Established the core molecular mechanism by showing ZNF471 is a KRAB-zinc-finger repressor that binds specific promoters and recruits KAP1 to deposit repressive H3K9me3, defining how it silences target genes.

   Evidence ChIP-PCR, ectopic expression and Western blot at TFAP2A and PLS3 promoters in cancer cell lines

   PMID:29610526

   Open questions at the time

   • Full target gene repertoire beyond TFAP2A and PLS3 not defined
   • Direct demonstration of KRAB domain requirement for KAP1 recruitment not shown
   • No structural basis for promoter recognition
2. 2020 Medium

   Revealed that ZNF471 can also act as a transcriptional activator, binding the MAPK10/JNK3 promoter to induce JNK3 and PCDH expression, broadening its role beyond pure repression.

   Evidence ChIP, RT-PCR and in vitro/in vivo functional assays in esophageal squamous cell carcinoma

   PMID:32089740

   Open questions at the time

   • Mechanism distinguishing activating from repressive promoter engagement unknown
   • No co-activator identified
   • Single lab
3. 2020 Medium

   Connected ZNF471 transcriptional activity to downstream oncogenic signaling, showing suppression of AKT and Wnt/β-catenin pathways inhibits EMT and stemness, and placed ZNF471 in a regulatory ncRNA axis.

   Evidence Knockdown/overexpression with Western blot and orthogonal cellular assays in breast cancer; luciferase sponge and rescue assays defining the LIFR-AS1/miR-942-5p axis in NSCLC

   PMID:32489316 PMID:33203470

   Open questions at the time

   • Direct transcriptional targets linking ZNF471 to AKT/Wnt not identified
   • Whether signaling suppression is direct or secondary to gene silencing unresolved
4. 2024 Medium

   Identified physical protein partners and a post-translational control point, showing ZNF471 interacts with BANP and that Asn358 N-glycosylation regulates its stability and nuclear localization for c-Myc repression.

   Evidence Co-IP/pull-down with BANP and PI3K/AKT/mTOR readouts in RCC; site-specific mutagenesis, fractionation and ChIP at the c-Myc promoter in tongue squamous carcinoma

   PMID:38169650 PMID:38749608

   Open questions at the time

   • BANP interaction lacks reciprocal/orthogonal validation in abstract
   • Enzyme mediating Asn358 glycosylation unknown
   • Functional consequence of BANP binding on transcription not mapped
5. 2026 Medium

   Extended the partner network and therapeutic relevance by defining a ZNF471-MIS18A axis that suppresses Wnt/β-catenin signaling and EMT and modulates drug sensitivity in HCC.

   Evidence Transcriptome sequencing, co-IP, Western blot and functional assays with clinical tissue in hepatocellular carcinoma

   PMID:42155792

   Open questions at the time

   • Interaction lacks explicit orthogonal validation
   • How MIS18A binding alters ZNF471 transcriptional output unknown

• How ZNF471 switches between repressive and activating modes, and how its physical partners (KAP1, BANP, MIS18A) coordinate on chromatin, remains unresolved.
• No genome-wide binding map
• No structural model of zinc finger-DNA recognition
• Determinants of activation versus repression undefined